Obeticholic acid (6-ECDCA) is a is a semi-synthetic bile acid analogue used to treat used to treat primary biliary cholangitis. Obeticholic acid is an orally available, potent and selective FXR agonist that exhibits anticholeretic and anti-inflammation effects.
Journal of medicinal chemistry, 45(17), 3569-3572 (2002-08-09)
A series of 6alpha-alkyl-substituted analogues of chenodeoxycholic acid (CDCA) were synthesized and evaluated as potential farnesoid X receptor (FXR) ligands. Among them, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) was shown to be a very potent and selective FXR agonist (EC(50) = 99 nM)
Tissue engineering and regenerative medicine, 18(2), 217-224 (2021-02-01)
Ballooned hepatocytes (BH) are a key histological hallmark of nonalcoholic steatohepatitis (NASH), yet their consequences for liver-specific functions are unknown. In our previous study, an experimental model of human induced-BHs (iBH) has been successfully developed based on cell sheet technology. This
Farnesoid X receptor (FXR) is a ligand-activated transcription factor involved in the control of bile acid (BA) synthesis and enterohepatic circulation. FXR can influence glucose and lipid homeostasis. Hepatic FXR activation by obeticholic acid is currently used to treat primary
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.